Detailed results found Dupixent improved overall asthma control in children aged six to 11 years old
News
Irish health service hit with ‘significant’ ransomware attack
Minister Ossian Smyth said the attack is “possibly the most significant cybercrime attack on the Irish State”
Biogen’s inherited eye disease gene therapy misses primary endpoint
Company maintained, however, that the study showed ‘positive trends’ across a number of prespecified secondary endpoints
Keytruda wins NICE backing in MSI-H/dMMR colorectal cancer
Immunotherapy recommended for use in patients with MSI/dMMR biomarkers
Sanofi, GSK’s COVID-19 vaccine achieves positive Phase II results
Companies previously delayed vaccine programme after Phase I/II study results found a low immune response in older adults
PharmaTimes are proud to confirm the launch of the 2021 Sales Awards
The 2021 Sales Awards have opened their doors for entry, continuing its legacy of uncovering and rewarding exceptional talent within the pharma sales sector.
Remove barriers restricting the research of controlled drugs, says RPS
Comments come in response to a consultation from the Advisory Council on the Misuse of Drugs
Alzheimer’s drug designed using Exscientia’s AI technology enters clinic
Drug candidate is being evaluated for the treatment of Alzheimer’s disease psychosis
NICE nod for BMS’ Opdivo in advanced oesophageal cancer
Cost-effectiveness watchdog recommends first immunotherapy for unresectable advanced oesophageal cancer
GSK, CureVac’s next-gen COVID-19 jab generates positive preclinical data
Vaccine induced strong immune responses in a rat model during preclinical testing
Abbott’s AI-powered coronary imaging platform deployed in the UK
Heart attack patients offered treatment with new technology at the Royal Free Hospital in London
Novo Nordisk’s weight loss drug semaglutide found to improve wellbeing
New results from a Phase IIIa study demonstrate benefits of drug for people with obesity ‘beyond weight loss’
Pfizer enrols first UK participant into global DMD gene therapy study
The CIFFREO study is expected to enrol 99 ambulatory male patients aged four to seven years old
NHS injects $160m into ‘elective accelerators’ to combat waiting lists
Accelerator sites will introduce new and ‘innovative’ ways of working to accelerate elective recovery
Astellas’ Xtandi bags additional MHRA approval in prostate cancer
Once-daily oral Xtandi approved for the treatment of adult men with metastatic hormone-sensitive prostate cancer
